Silversea, Oceania reveal months-long world cruises in 2027, 2028
AI-assisted summary
Silversea Cruises and Oceania Cruises announced new world cruises with itineraries lasting over 100 days.
Silversea's 132-day cruise will visit 29 countries and Oceania's 180-day cruise will visit 46 countries.
Both cruises depart from Miami in January of 2027 and 2028, respectively.
Prices for both cruises start at over $70,000 per person.
Two upscale cruise lines announced globe-spanning cruises this week, each visiting dozens of countries.
Silversea Cruises revealed the details of its 2028 World Cruise on Thursday, which will visit 29 countries over 132 days. 'Our 2028 World Cruise, An Ode to the Moment, is designed to slow time, offering deeper exploration of each destination,' Bert Hernandez, the line's president, said in a news release. 'With our unrivaled destination expertise, we guide guests to both iconic landmarks and hidden gems, ensuring they experience the world at its finest.'
Oceania Cruises also announced a lengthy new itinerary on Wednesday, with its 2027 Around the World cruise scheduled to sail for 180 days with stops in 46 countries.
'Spanning six months at sea, this extraordinary voyage offers the rare opportunity to circumnavigate the globe while seamlessly connecting diverse continents, rich cultures, and authentic cuisines, creating an unforgettable experience for our guests,' Jason Montague, the line's Chief Luxury Officer, said in a separate release.
Here's what to know about the itineraries.
Need a break? Play the USA TODAY Daily Crossword Puzzle.
When are Silversea and Oceania's new world cruises?
Silversea's cruise will depart from Miami on Jan. 5, 2028, on the line's 392-guest Silver Shadow ship. Oceania's sailing will also begin in Miami on Jan. 6, 2027, aboard Oceania Vista, which can accommodate 1,200 passengers at double occupancy.
What is a world cruise? What's included, when to book and more
Where will the cruises go?
Silversea's itinerary will be divided into nine chapters, beginning with a deep exploration of the Caribbean en route to Cartagena, Colombia, followed by visits to the Panama Canal, Rio de Janeiro for Carnival, Mauritius, Abu Dhabi and more. Passengers will stop in 58 destinations in total, with 17 overnight stays, and can partake in activities like a Columbian Coffee Workshop and an exclusive evening of cuisine, music and dancing at Peru's Pedro de Osma Museum. The cruise will end in Nice, France.
Oceania's cruise will also explore the Caribbean and make its way to the Panama Canal, 'island-hop' from Hawaii to Fiji, per the line's release, and transit along the coast of Australia to cities like Sydney, Cairns and Darwin. Guests will also spend over two months in Asia sailing around Thailand, Japan and more. Shore excursions for small groups, onboard art classes and more will be on offer, as well. Guests will disembark in London (they can also choose from longer 244-day and shorter 127-day options).
How much do the cruises cost?
Silversea's cruise currently starts at $74,900 per guest, based on double occupancy. Oceania's 180-day itinerary currently starts at $76,199 per person, based on double occupancy.
Nathan Diller is a consumer travel reporter for USA TODAY based in Nashville. You can reach him at ndiller@usatoday.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
24 minutes ago
- Bloomberg
Bain-Backed Group Seeks $454 Million Loan for Winemaker Vinarchy
A consortium called Australian Wine Holdco Ltd. that includes Bain Capital and Sona Asset Management Ltd. is seeking an A$700 million ($454 million) loan for a winemaker they acquired last year, people familiar with the matter said. Commonwealth Bank of Australia has underwritten the financing for Vinarchy, a new entity created via the merger of Accolade Wines and Pernod Ricard SA 's former wine division, the people said, who asked not to be identified discussing a private matter. The bank is tapping other financiers to participate in the syndicated borrowing with a tenor of three years, comprised of term and revolving credit tranches, they added.
Yahoo
3 hours ago
- Yahoo
VEEM (ASX:VEE) shareholders have earned a 18% CAGR over the last five years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you can make far more than 100% on a really good stock. For example, the VEEM Ltd (ASX:VEE) share price has soared 120% in the last half decade. Most would be very happy with that. Unfortunately, though, the stock has dropped 4.9% over a week. Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During five years of share price growth, VEEM achieved compound earnings per share (EPS) growth of 9.1% per year. This EPS growth is slower than the share price growth of 17% per year, over the same period. So it's fair to assume the market has a higher opinion of the business than it did five years ago. And that's hardly shocking given the track record of growth. You can see below how EPS has changed over time (discover the exact values by clicking on the image). It might be well worthwhile taking a look at our free report on VEEM's earnings, revenue and cash flow. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, VEEM's TSR for the last 5 years was 130%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return. VEEM shareholders are down 51% for the year (even including dividends), but the market itself is up 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 18%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 1 warning sign for VEEM that you should be aware of before investing here. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Individual investors account for 52% of EVE Health Group Limited's (ASX:EVE) ownership, while insiders account for 25%
EVE Health Group's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 48% of the business is held by the top 18 shareholders Insider ownership in EVE Health Group is 25% AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Every investor in EVE Health Group Limited (ASX:EVE) should be aware of the most powerful shareholder groups. With 52% stake, individual investors possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). And individual insiders on the other hand have a 25% ownership in the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Let's take a closer look to see what the different types of shareholders can tell us about EVE Health Group. Check out our latest analysis for EVE Health Group We don't tend to see institutional investors holding stock of companies that are very risky, thinly traded, or very small. Though we do sometimes see large companies without institutions on the register, it's not particularly common. There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company. It is also possible that fund managers don't own the stock because they aren't convinced it will perform well. EVE Health Group's earnings and revenue track record (below) may not be compelling to institutional investors -- or they simply might not have looked at the business closely. We note that hedge funds don't have a meaningful investment in EVE Health Group. Everhoney Biotech Australia Pty. Ltd. is currently the company's largest shareholder with 13% of shares outstanding. For context, the second largest shareholder holds about 9.6% of the shares outstanding, followed by an ownership of 6.2% by the third-largest shareholder. Furthermore, CEO Gregory Fry is the owner of 2.5% of the company's shares. On studying our ownership data, we found that 18 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our information suggests that insiders maintain a significant holding in EVE Health Group Limited. Insiders have a AU$53m stake in this AU$211m business. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling. The general public, who are usually individual investors, hold a substantial 52% stake in EVE Health Group, suggesting it is a fairly popular stock. With this amount of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to vote on acquisitions or mergers that may not improve profitability. We can see that Private Companies own 23%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research. While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with EVE Health Group (at least 1 which doesn't sit too well with us) , and understanding them should be part of your investment process. If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
